How Patients and Providers Weigh the Risks and Benefits of Long-Term Opioid Therapy for Cancer Pain.


Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
07 2021
Historique:
pubmed: 4 2 2021
medline: 12 8 2021
entrez: 3 2 2021
Statut: ppublish

Résumé

To understand how patients and providers weigh the risks and benefits of long-term opioid therapy (LTOT) for cancer pain. Researchers used VA approved audio-recording devices to record interviews. ATLAS t.i., a qualitative analysis software, was used for analysis of transcribed interview data. Participants included 20 Veteran patients and 20 interdisciplinary providers from primary care- and oncology-based practice settings. We conducted semistructured interviews and analyzed transcripts used thematic qualitative methods. Interviews explored factors that affect decision making about appropriateness of LTOT for cancer related pain. We saturated themes for providers and patients separately. Factors affecting patient decision-making included influence from various information sources, persuasion from trusted providers, and sometimes deferral of the decision to their provider. Relative prioritization of pain management as the focal patient concern varied with some patients describing comparatively more fear of chemotherapy than opioid analgesics, comparatively more knowledge of opioids in relation to other drugs;patients expressed a preference to spend the limited time they have with their oncologist discussing cancer treatment rather than opioid use. Factors affecting provider decision making included prognosis, patient goals, patient characteristics, and provider experience and biases. Providers differed in how they weigh the relative importance of alleviating pain or avoiding opioids in the face of treating patients with cancer and histories of substance abuse. Divergent perspectives on factors need to be considered when weighing risks and benefits. Policies and interventions should be designed to reduce variation in practice to promote equal access to adequate pain management. Improved shared decision-making initiatives will take advantage of patient decision-making factors and priorities.

Identifiants

pubmed: 33534632
doi: 10.1200/OP.20.00679
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1038-e1047

Auteurs

Karleen F Giannitrapani (KF)

VA Palo Alto Health Care System, Center for Innovation to Implementation (Ci2i), Menlo Park, CA.
Stanford University School of Medicine, Stanford, CA.

Soraya Fereydooni (S)

VA Palo Alto Health Care System, Center for Innovation to Implementation (Ci2i), Menlo Park, CA.
Stanford University School of Medicine, Stanford, CA.

Maria J Silveira (MJ)

Geriatric Research Education Clinical Center (GRECC), Ann Arbor VA Health Care System, Ann Arbor, MI.
University of Michigan, Michigan, MI.

Azin Azarfar (A)

VA Palo Alto Health Care System, Center for Innovation to Implementation (Ci2i), Menlo Park, CA.
University of Central Florida, Orlando, FL.

Peter A Glassman (PA)

VA Pharmacy Benefits Management Services, Washington, DC.
David Geffen School of Medicine at University of California Los Angles, Los Angeles, CA.

Amanda Midboe (A)

VA Palo Alto Health Care System, Center for Innovation to Implementation (Ci2i), Menlo Park, CA.
Stanford University School of Medicine, Stanford, CA.

Maria Zenoni (M)

Pain Research, Informatics, Multimorbidities and Education (PRIME) Center, VA Connecticut Health Care System, West Haven, CT.

William C Becker (WC)

Pain Research, Informatics, Multimorbidities and Education (PRIME) Center, VA Connecticut Health Care System, West Haven, CT.
Yale School of Medicine, New Haven, CT.

Karl A Lorenz (KA)

VA Palo Alto Health Care System, Center for Innovation to Implementation (Ci2i), Menlo Park, CA.
Stanford University School of Medicine, Stanford, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH